Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards' chance for fresh blood as CFO retires

This article was originally published in Clinica

Executive Summary

On the same day that stuttering heart valve specialist Edwards Lifesciences announced a $750 million share repurchase program in a bid to placate shareholders, its CFO said he would retire later this year. The departure of Thomas Abate, who has been at the company for 31 years and turns 60 in August, is “a bit surprising but understandable given recent misses and related stock performance”, said Jefferies analyst Raj Denhoy. It could even be a positive, giving Edwards chance to bring in fresh blood after a difficult period.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel